ClinicalTrials.gg
CompletedNCT05814939Updated Jul 29, 2024

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

A Phase 2 interventional study of VC005 tablets and Tofacitinib Citrate Tablets in Active Ankylosing Spondylitis, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
26th of 62
180 · median 150
Started
2023
with 6 others
Phase 2
11 of 76
none open now
Registered
48th of 76
by date
Lead sponsor
2 of 76
Jiangsu vcare pharmaceutical technology co., LTD

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 26th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 11 in phase 2, and was the 48th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

03

Conditions studied

  • Active Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject understands and voluntarily signs the form (ICF) and is willing and able to comply with the study protocol;
  2. The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
  3. The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis (AS can be diagnosed by having Article ④ and any one of Articles ① to ③): ① lower back pain lasting for at least 3 months, with pain improving with activity but not with rest; ② limited movement of the lumbar spine in the anterior-posterior and lateral flexion directions; ③ thoracic extension less than normal for the same age and sex; ④ bilateral sacroiliac arthritis grade II-IV, or unilateral sacroiliac arthritis grade III-IV;
  4. The subject had active disease prior to the screening visit and randomization, defined as follows: Bath AS Disease Activity Index (BASDAI) score ≥ 4 and a spinal pain score (BASDAI question 2) ≥ 4 (see Annex 6 for scoring criteria);
  5. Subjects who have been treated with non-steroidal anti-inflammatory drugs (NSAIDs) and still have active disease, or who have discontinued NSAIDs due to intolerance; defined as follows: subjects must have had at least 2 cumulative inadequate clinical responses to the recommended dose (≥2 weeks of each NSAID and ≥4 weeks of total use) or intolerance to at least 2 different oral NSAIDs. Intolerance defined as discontinuation of treatment with NSAIDs due to associated adverse events (e.g., allergic reactions, gastrointestinal signs or symptoms, etc.);
  6. Subjects taking treatment with NASIDs at the time of screening, requiring stable dose continuation for ≥ 2 weeks prior to randomization; no change in drug dose during the study period except for emergencies; if not taking, discontinuation for at least ≥ 2 weeks prior to randomization;
  7. If subjects are enrolled in the study on a combination of methotrexate (MTX), salazosulfapyridine (SASP) and/or hydroxychloroquine (HCQ), subjects must receive a stable dose of MTX (≤25 mg/week) and/or SASP (≤3 g/day) and/or HCQ (≤400 mg/day) for at least 28 days prior to the baseline visit. A maximum of two background csDMARDs allowed in combination;
  8. Subjects taking oral at screening at doses ≤10 mg/day of prednisone (or equivalent doses of other glucocorticoids) that need to be continued for ≥4 weeks prior to randomization; if subjects are not taking oral glucocorticoids, they need to be off them for at least ≥4 weeks prior to randomization;
  9. The subject has received ≤ 1 prior treatment with a biologic agent prior to randomization. Subjects previously treated with biologic agents must have been off ≥ 6 half-lives prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Presence of the following diseases or history of disease:
  1. A known or suspected history of complete spinal ankylosis, or clinically and imaging confirmed complete spinal ankylosis;
  2. A history of any other rheumatic disease;
  3. Patients with a combination of severe extra-articular manifestations, such as hyperthermia, interstitial pneumonia, pleurisy, pericarditis, severe vasculitis, or neurological pathology;
  4. Patients with current or recent serious, or progressive, or uncontrolled disease, including: hepatic, renal, hematologic, gastrointestinal, endocrine, metabolic, respiratory, cardiovascular, or neurologic disease; or patients who, in the opinion of the investigator, may affect patient safety or compliance;etc.

2.Any of the following laboratory test indicators are met at the time of the screening test:

  1. Those who test positive for the following bacteria or viruses at screening, such as , syphilis, Virus (HBSAg, HBeAg, Hepatitis B Virus-DNA, anyone positive for any of the three), Virus (positive for anti-Hepatitis C Virus antibodies); If screening stage hepatitis B surface antigen negative (HBsAg-) and anti-hepatitis B core antibody positive (HBcAb+), additional quantitative Hepatitis B Virus-DNA test is required and excluded if quantitative > normal value;
  2. Routine blood count: white blood cell count (WBC) \<3×109/L, (ANC) \<1.5×109/L, absolute lymphocyte count (ALC) \<0.8×109/L, (PLT) \<100×109/L, (Hb) \<100 g/L;etc.
  1. Is taking or has a history of taking medication that:
  1. Those who are receiving any other csDMARDs or biologic DMARDs (except MTX, SASP, HCQ in the inclusion criteria) or other prohibited concomitant medications; if previous use of csDMARDs such as thalidomide, hydroxychloroquine or leflunomide, those who discontinued thalidomide, hydroxychloroquine, etc. for ≤ 4 weeks and leflunomide for ≤ 8 weeks prior to randomization (using criteria subjects not more than 28 days after Kauleenamine treatment or active carbon elution were not allowed to be enrolled in the trial);
  2. Those who have been treated with any tyrosine kinase (JAK) inhibitor (e.g. Tofacitinib, Baricitinib, Upadacitinib, etc.);etc.
  1. Those who may be allergic to VC005, similar drugs or their 5. Those with substance abuse or alcohol dependence 6. Subjects who, in the opinion of the investigator, may be at risk of gastrointestinal perforation during the course of the trial 7. Those who have participated in a clinical trial with any drug or device within 12 weeks prior to screening and have used that drug or device 8. Subjects who have a history of major surgery, joint surgery within 6 months prior to screening or who are scheduled to have surgery during the trial 9. Female patients who are planning to become pregnant or who are pregnant or breastfeeding, or who are unable to use effective throughout the trial and for 3 months after the end of the trial (see Appendix 14 for details) 10. Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    VC005 Tablets Low Dose groups

    Drug: VC005 tablets

  • Experimental
    VC005 Tablets Medium Dose groups

    Drug: VC005 tablets

  • Experimental
    VC005 Tablets High Dose groups

    Drug: VC005 tablets

  • Active comparator
    Tofacitinib Citrate Tablets groups

    Drug: Tofacitinib Citrate Tablets

  • Placebo comparator
    VC005 Tablets Placebo groups

    Drug: VC005 Tablets Placebo

Interventions

  • VC005 groups repeat administration for 12 weeks

  • Tofacitinib Citrate groups repeat administration for 12 weeks

  • DrugVC005 Tablets Placebo

    VC005 placebo groups repeat administration for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of patients achieving ASAS20

    Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.

    Time frame: Week 12

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in May 2024, 12 months.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 18, 2023
StartActual
Apr 26, 2023
Primary completionActual
May 11, 2024
CompletionActual
May 11, 2024
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05814939
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 26, 2023
Primary completion
May 11, 2024
Completion
May 11, 2024
Last update
Jul 29, 2024

Study contacts

Zhanguo Li
principal investigator · Peking University People's Hospital
Xu Liu
principal investigator · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VC005

Start the discussion